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HEPATIC TUMOURS
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For treatment of malignancies, physical and metabolic differences between tumour cells and host cells
have guided the development of new approaches. In this review, two new approaches to be used in the
treatment of liver malignancies are outlined: ischaemic therapy and interferences with the glucose
metabolism. Ischaemic therapy of liver malignancies has been used in different forms during the last 20
years: from ligation of the hepatic artery, embolization of the arterial tree, transient occlusion of the
hepatic artery to the present day use of temporary, intermittent, transient hepatic arterial occlusion. The
beneficial effect of ischaemic therapy on malignancies is supposed to depend on oxygen and nutritional
deficiency, formation of oxygen-derived free radicals and loss of function in cellular enzymes. The tumour
cells seem thereby to be more sensitive than the host cells. Also, ischaemia might potentiate the effect of
cytotoxic drugs. Intereferencies with glucose metabolism might be directed either towards the
exaggerated tumour glycolysis, for example by glucose analogues like 2-deoxy-glucose, or towards the
exaggerated host gluconeogenesis, for example by hydrazine sulphate. These treatments result in
reduction of the glucose availability in the intracellular glucose metabolism in the tumour cells and have
experimentally been demonstrated to be correlated to reduced tumour growth. It is concluded that both
these approaches, ischaemic therapy and manipulations with the glucose metabolism, seem promising for
the future. What is needed now is research to clarify the mechanims behind the effects, to establish their
full consequences, and to identify the clinical use of these treatments and their possible combinations.
KEY WORDS: Cancer, malignancy, liver, ischaemia, treatment, glucose metabolism, glucose oxidation,
glycolysis, 2-deoxy-glucose, gluconeogenesis, hydrazine.
I. INTRODUCTION
For treatment of malignancies, physical and metabolic differences between tumour
cells and host cells have guided the development of new approaches. For example,
the greater sensitivity to cytotoxic agents in rapidly growing tumour cells compared
to that in normal cells has made feasible the intense use of various cytotoxic drugs for
treatment. Likewise, a sensitivity for radiation and hyperthermia greater in tumour
cells than in normal cells has firmed the use of these models in cancer treatment. We
will here focus attention on two other new approaches to be used in the treatment of
malignancies: ischaemic therapy and interferences with the tumour glucose
metabolism. For both these new approaches, differences in tumour versus host-cell
function may explain the beneficial effects, and, furthermore, knowledge of these
differences may be used when optimizing the therapy.
Correspondence and reprint requests to: Dr Bo Ahr6n, Department of Surgery, Lund University, 22185
Lund, Sweden.
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II. HEPATIC DEARTERIALIZATION
Ischaemic therapy of liver malignancy was intitiated when it was realized that liver
tumour cells preferentially are nourished by the arterial blood supply, whereas
hepatocytes, on the contrary, are supplied mainly by portal bloodI’L. Exceptions
exist, however, since cells in small tumours and cells located peripherally in the
tumours seem to be nourished also by the portal blood3’4. In the earlier phase of this
development, ligation or embolization of the hepatic artery was performed5-8. This
manipulation was found to reduce tumour growth, at least initially, but was also
found to initiate collateral formation, which counteracts the aim of the ligation9.
Therefore, a method of temporary dearterialization was developed: slings were
introduced around the hepatic artery and removed after 16 hours). This temporary
dearterialization seemed to prevent collateral formation, but the technique was a
one-shot treatment, which to be repeated necessitated a new laparatomy.
Nevertheless, it was found to be beneficial for carcinoid tumours, with regard both to
tumour volume reduction and to improvement of the carcinoid syndrome11.
Recently, a new device allowing repeated hepatic arterial occlusion has been
developed12. The occluder is connected to a subcutaneous injection port through
which fluid may be injected, leading to hepatic artery occlusion (Figures i and 2). It
is hoped that the repeatedly undertaken temporary dearterialization may prevent
collateral formation and still retain the tumour reduction effect13. It has to be
emphasized here that these arterial occlusion models all need the performance of an
extensive devascularization procedure of the liver to make the hepatic artery the only
supplier of arterial blood to the liver.
Figure Implantable device for intermittent, repeatedly undertaken dearterialization of the liver.
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Figure 2 The implantable occluder applied to the hepatic artery and connected to a port.
Ischaemic Effects of Dearterialization
A main effect of hepatic dearterialization is the resulting ischaemia. This eventually
causes hypoxia in the tumours, as has been demonstrated by the clamping of
experimental rodent tumoursTM. The oxygen lack halts cellular respiration, which
subsequently results in cell damage. That oxygen lack indeed results in tumour
necrosis has been demonstrated in a multicellular spheroid model of tumour
microregions15. However, the same study also showed that necrosis may develop
despite adequate oxygen supply, illustrating that other factors, such as glucose
deprivation, acidosis or lactate accumulation, may also be o importance or necrosis
development5. It is of interest to mention that small tumours might be more
sensitive to ischaemia than large tumours, since they have a higher oxygen
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consumption rate16. Although tumour cells might thus be injured by the ischaemia
occuring during dearterialization, the oxygen lack might also influence normal liver
cells. A goal in this mode of treatment is to minimize the negative influence on the
normal cells and still retain the beneficial effects on the tumours. Before reaching this
goal, we have to analyze the characteristics and extent of ischaemia-induced injuries
to the normal liver. It must, however, be mentioned that the tumours seem to be
more sensitive to hypoxia than normal cells, probably because the rapid
proliferation, notably of the tumour vascular endothelium17.
Injured normal liver cells during and immediately after ischaemia have been
demonstrated by the use of histochemical dye techniquesTM. Flocculent densities in
the mitochondrial areas, as a sign of cell injury, have also been shown at 24 h after
liver ischaemia in the rat19. Furthermore, the activity of the mitochondrial enzyme
glutamate dehydrogenase is concomitantly decreased9. Moreover, after 3 h
ischaemia of the rat liver, the activity of phospholipase A in the mitochondria has
increased, which has resulted in accumulation of ly_sophospholipids and a subsequent
injured control of the innner mitochondrial layer2. Also, after 5 h ischaemia of the
rat liver, serum levels of the mitochondrial enzyme ornithine carbamyl transferase
have increased21. Injuries to the mitochondria seem, therefore, to be a common
manifestation of liver ischaemia. However, other hepatic functions might also be
altered by ischaemic treatment. Thus, microvilli of the bile canaliculi have been
demonstrated to disappear after 15 min ischaemia, and the activity of the plasma
membrane enzyme 5’-mononucleotidase is lowered after 30 min ischaemia22.
Lysosomal alterations have also been seen during hepatic ischaemia: the serum
activity of the lysosomal enzyme [3-glucosaminidase in the rat is lowered after 1 h
hepatic ischaemia23, and serum lysosomal enzyme activities in man are increased
24after hepatic dearterialization In addition, hypoxia and ischaemia in the perfused
pig liver have been shown to impair the hepatic galactose elimination rate, inhibit
ATP phosphorylation and increase the lactate output25. However, depite 80 min
ischaemia, almost complete recovery occurred25.
Other Effects of Dearterialization
Besides the hypoxic-ischaemic effects of clamping procedures of the hepatic artery,
these also seem to increase sensitivity to radiation and cytotoxic drugs, induce the
formation of oxygen-derived free radicals, and restrict the nutritional supply to the
tumours. These effects might also be of importance, perhaps as important as the
ischaemic-hypoxic effects of dearterialization. That clamping enhances sensitivity to
radiation has been demonstrated in rodent mammary tumoursTM, and the
potentiation of cytostatic drugs is exemplified by the anticancer agent mitomycin C,
which has been demonstrated to be more cytotoxic to hypoxic tumour cells than to
cells under normal oxygen tension26. Likewise, cisplatin seems to reduce the
oxidative metabolism in polymorphonuclear cells, which might be indicative of a
hypoxia-like action, which then will be further enhanced by hypoxia27.
Ischaemic therapy has also been demonstrated to induce the formation of oxygen-
derived free radicals28. These toxic substances (superoxide, hydrogen peroxide and
hydroxyl radicals) are produced under hypoxic conditions and during reperfusion
after hypoxia29. A mechanism behind their production is the reduction of
hypoxanthine to xanthine by the enzyme xanthine dehydrogenase, which under
hypoxic conditions functions as a xanthine oxidase3. Under normal conditions,
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protective mechanisms against this conversion exist, but these are impaired during
hypoxia31. Consequently, xanthine oxidase inhibition by allopurinol has been
demonstrated to prevent a long-standing reduction in protein synthesis after liver
ischaemia in rats", and the radical scavenger disulfiram has been demonstrated to
reduce the number of injured liver cells after 90 min ischaemia in rats33. Likewise, in
one study, the scavenger glutathione was protective against rat liver ischaemia when
intracellular calcium distribution, dye exclusion and membrane potential were
v 34"n estlgated Hence, dearterialization might be deleterious to cells also through the
production of oxygen-derived free radicals35.
Clamping of the arterial supply reduces the nutritional supply to the cells. To what
extent this may explain the cell injury and whether tumour cells are more vulnerable
to this effect are questions that remain to be settled. However, it has been shown that
protein synthesis in the liver is reduced by ischaemia36-37, and it has also been
demonstrated that glucose deprivation to tumour cells in vitro results in
derangements of protein synthesis similar to those from hypoxia38. Furthermore,
central tumour necrosis is induced not only by hypoxia but also by lack of glucoselS.
Thus, effects other than pure hypoxia seem to evolve by clamping and
dearterialization. Of these, exaggerated sensitivity to cytotoxic treatment,
superoxide production and deprivation of the nutritional supply seem to be most
interesting in relation to tumour treatment. Combined treatment might be scheduled
upon this knowledge.
Dearterialization: Conclusions
As outlined in the discussion so far, the full consequences and exact mechanism of
ischaemic therapy of liver malignancy are not established. It is clear, however, that
not only hypoxic effects are induced, but also exaggerated sensitivities to cytotoxic
substances, formation of oxygen-derived free radicals, and reduction of the
nutritional supply. Experimentally, ischaemia has been shown to impair tumour
growth39 and, for future development and research, a small implantable device for
repeated temporary hepatic dearterialization in the rat has been developed4. It will
be used to study the consequences of hepatic ischaemia and to optimize treatment.
Clinically, hepatic dearterialization used for 16 h has been shown to reduce carcinoid
tumour growth11. Studies on the theoretically more optimal repeated temporary
dearterialization are under way. Future research must establish the time dependency
of effects on the tumour and the host cells to settle the optimal schedule for
treatment. The optimal treatment should use the beneficial effect of tumour growth
retardation but avoid ischaemic effects on normal liver cells. At present, a schedule
of hepatic dearterialization 1 h twice daily is considered most proper and used in our
department.
III. MANIPULATION OF GLUCOSE METABOLISM
Several different types of tumour cells are characterized by deriving their energy
mainly from the glycolytic pathway and thus they show a great dependency on
glucose supply for their survival. This characteristic was recognized several decades
ago41 and has recently been reconfirmed by the demonstration that tumours exhibit
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high rates of glucose utilization and lactic acid production42. This high rate of
glycolysis by tumours could be a mechanism behind the exaggerated glucose
turnover rate in tumour patients, as shown by the glucose isotope tracer
technique43’44. This abnormally high dependency on glucose is a potential difference
between tumour and host cells to which intervention may be directed. Two different
approaches may then be undertaken: reduction of the glycolytic activity and
restrainment of the glucose supply.
Inhibition of Glycolysis
The glycolytic pathway is the process in which glucose is converted to substrates for
the tricarboxylic acid cycle and in which the energy of the glucose molecule is
liberated as ATP. The pathway involves several different enzyme steps converting
glucose-6-phosphate to pyruvic and lactic acid (Figure 3). The glycolytic flow can be
inhibited by the substance 2-deoxyglucose, which is a glucose analogue (Figure 4). 2-
Deoxyglucose inhibits both the glucose uptake into the cell, and the hexokinase that
catalyzes the phosphorylation of glucose (i.e. the formation of glucose-6-
phosphate)45’46. 2-Deoxyglucose is by itself converted to a 2-deoxyglucose-6-
phosphate, but this substance is not isomerized to fructose-6-phosphate, and thus
does not enter the glycolytic pathway further. 2-Deoxyglucose might also inhibit the
conversion of glucose-6-phosphate to glucose-l-phosphate47. A marked reduction in
glycolysis by 2-deoxyglucose has been demonstrated in vitro in leukaemic leukocytes
48 49and in HeLa cells Since tumour cells, as outlined above, seem more dependent
on this pathway for their energy supply than other cells, 2-deoxyglucose might be
used in the treatment of malignancies. This has been investigated experimentally in a
few studies. In one study, the effects of 2-deoxyglucose on tumour growth in three
different tumour models in the mouse were investigated: in a leukaemia, a
transplantable carcinoma, and a mast cell tumour5. 2-Deoxyglucose was found to
reduce tumour growth and induce a prolongation of the survival time5.
Furthermore, a recent study on fibrosarcoma in the rat demonstrated that upon
systemic administration 2-deoxyglucose reduced the tumour growth51, and a recent
C2OH C li’12OH
C OH H C C OH H C
H OH H H
Gtucose 2-Deoxy-gtucose
Figure 4 The chemical structures of glucose and 2-deoxyglucose, illustrating that 2-deoxyglucose lacks the
hydroxyl group in carbon position 2.
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Figure 3 A simplified outline of the intracellular metabolic fate of glucose, showing the glycolytic pathway
in which glucose-6-phosphate is converted to pyruvic and lactic acid. 2-Deoxyglucose inhibits this pathway
by inhibiting the cellular uptake of glucose and by inhibiting the enzyme hexokinase. Also illustrated in
the figure is the enzyme pyruvic acid kinase, which in glycolysis converts phosphoenolpyruvic acid to
pyruvic acid.
study on HeLa cells showed that 2-deoxyglucose at high-dose levels inhibited DNA
repair after radiation49. However, in two other experimental tumour models in the
mouse, a fibrosarcoma and a mammary adenocarcinoma, 2-deoxyglucose failed to
alter tumour growth when administered at dose levels high enough to produce
systemic toxicity5=. This illustrates that different tumours might respond with
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different sensitivity to the inhibition of glycolysis, and that the systemic toxicity of
glucose analogues might restrict their use. The toxicity depends on the
neuroglycopenia, since a competition with glucose in the glycolytic pathway also
occurs within the brain, which is strictly dependent on glucose for its metabolism.
Neuroglycopenia causes neurological disturbances that may lead to seizures and
death52. Also, neuroglycopenia induces reflex activation of the autonomic system, as
evidenced by enhanced plasma levels of noradrenaline53 and a cholinergically
mediated stimulation of insulin secretion54.
In conclusion, the approach of inhibiting the glycolytic pathway in tumours seems
valid and might guide future research. What is needed is, first, to establish which
malignancies are sensitive to this mode of treatment and, secondly, to develop
inhibitors of glycolysis that exert effects on tumour metabolism without affecting
neural glycolysis. Regional administration of glucose analogues might also reduce
toxic systemic effects. Also, since hypoxic cells seem more influenced by glucose
deprivation than normal cells, the combined use of glucose analogues and
dearterialization procedures has to be investigated.
Inhibition of Gluconeogenesis
The formation of glucose from non-carbohydrate precursors, mainly amino acids
and lactate, is called gluconeogenesis (Figure 5). This pathway is often exaggerated
in cancer patients because of the general catabolism, with an exaggerated production
of amino acids from the protein breakdown, of glycerol from the massive lipid
mobilization, and of lactate from the enhanced glycolytic pathway in the tumours.
This massive gluconeogenesis provides the tumour with amounts of glucose sufficient
for the exaggerated glycolysis, and might be the pathway for the high energy
expenditure in these patients and, possibly, the sign of cancer cachexia. It has
Gtucose
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Figure 5 A simplified outline of the metabolic pathways of gluconeogenesis, showing the conversion of
amino acids, lipids and carbohydrates to glucose via the tricarboxylic acid cycle intermediates. Illustrated
is the enzyme phosphoenolpyruvate carboxykinase, which converts oxaloacetate via pyruvic acid to
phosphoenolpyruvic acid, and which is inhibited by hydrazine sulphate.
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therefore been proposed that inhibition of the exaggerated gluconeogenesis would
reverse, or at least diminish, cancer cachexia, and also by diminishing the provision
of glucose to tumour cells inhibit tumour growths6. Theoretically, inhibition of
gluconeogenesis could be achieved by inhibition of the enzyme
phosphoenolpyruvate carboxykinase, i.e. the enzyme catalyzing the conversion of
pyruvic acid to phosphoenolpyruvic acid57. By inhibition of this enzyme,
gluconeogenesis would be selectively inhibited, without any inhibition of glycolysis,
which lacks this enzyme in its pathway, since the conversion of phosphoenolpyruvic
acid kinase to pyruvic acid in the glycolytic pathway is catalyzed by pyruvic acid kinase57.
Hydrazine sulphate was found to be an agent that specifically inhibits
phosphoenolpyruvate carboxykinase; the inhibition was found to be irreversible and
readily obtained in vivo as well as in vitro8. Hydrazine sulphate belongs to a group of
anti-cancer agents, of which the most well known is procarbazine59. Hydrazine
sulphate has been tested experimentally and found to inhibit growth of a variety of
experimental tumours, e.g. Walker 256 carcinosarcoma, Murphy-Sturm
lymphosarcoma, B-16 melanoma, and fibrosarcoma and adenocarcinoma of the lung
and breast in mice6-63. Subsequently, the drug was tested in a group of 84 patients
with disseminated cancer and found to improve the patients subjectively in 70% and
objectively in 17% within three months of treatment64. Furthermore, the effects of
hydrazine sulphate were evaluated in a group of 233 patients with disseminated
tumours during a period of 1-6 months, and the drug was found to reduce tumour
growth in 50% of cases65. It also improved cancer cachexias7’66. A recent double-
blind trial on 12 malnourished patients with lung cancer also showed that, after just
30 days of treatment, improvement of cancer cachexia was obtained66. However,
negative results have also been seen: in a study on 25 patients with solid malignant
tumours, no subjective or objective improvement was observed during a 4-week
treatment period with hydrazine sulphate67. It might thus be concluded so far that
inhibition of gluconeogenesis by the use of hydrazine sulphate improves metabolic
and nutritional indices in patients with cancer cachexia, but it is too early to conclude
whether this is combined with reduction in tumour growth and/or improved survival
rates67. The studies with hydrazine sulphate, however, have illustrated the possibility
of interfering with host metabolism, and this, perhaps together with manipulations
directed towards tumour metabolism, might turn out a feasible direction for future
research.
IV. CONCLUSIONS
This review has focused on two new approaches for treatment of malignancies with
special reference to hepatic malignancies: dearterialization and manipulation of the
glucose metabolism. Both these approaches seem promising for the future.
However, what is needed now is research undertaken to clarify the exact mechanisms
behind the effects obtained by the different treatments, to establish their full
consequences for both tumour and host cells, and to identify the clinical use of these
treatments and their possible combinations.
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